2. Search Result
Search Result
Results for "

Abiraterone

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-70013
    Abiraterone
    Maximum Cited Publications
    17 Publications Verification

    CB-7598

    		 Cytochrome P450 Cancer
    Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    <em>Abiraterone</em>
  • HY-109619
    D4-abiraterone

    Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite

    		 Androgen Receptor Cytochrome P450 Cancer
    D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
    D4-<em>abiraterone</em>
  • HY-148376
    Abiraterone N-oxide

    		Drug Metabolite Cancer
    Abiraterone N-oxide is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
    <em>Abiraterone</em> N-oxide
  • HY-148377
    Abiraterone sulfate N-oxide

    		Others Cancer
    Abiraterone sulfate N-oxide is a carboxylic acid. Abiraterone sulfate N-oxide also is a major metabolite of Abiraterone (HY-70013). Abiraterone sulfate N-oxide can be used for the research of prostate cancer .
    <em>Abiraterone</em> sulfate N-oxide
  • HY-145786
    Abiraterone decanoate

    		Cytochrome P450 Cancer
    Abiraterone decanoate is a potent Abiraterone proagent. Abiraterone decanoate provide a controlled release of Abiraterone and long-acting CYP17 inhibition with intramuscular (IM) delivery .
    <em>Abiraterone</em> decanoate
  • HY-148375
    Abiraterone sulfate

    		Drug Metabolite Others
    Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .
    <em>Abiraterone</em> sulfate
  • HY-75054
    Abiraterone acetate
    10+ Cited Publications

    CB7630

    		 Cytochrome P450 Cancer
    Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    <em>Abiraterone</em> acetate
  • HY-75054R
    Abiraterone acetate (Standard)
    10+ Cited Publications

    CB7630 (Standard)

    		 Cytochrome P450 Cancer
    Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    <em>Abiraterone</em> acetate (Standard)
  • HY-75054S
    Abiraterone acetate-d4

    CB7630-d4

    		 Isotope-Labeled Compounds Cytochrome P450 Cancer
    Abiraterone acetate-d4 is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).
    <em>Abiraterone</em> acetate-d4
  • HY-70013S
    Abiraterone-d4

    CB-7598-d4

    		 Cytochrome P450 Cancer
    Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
    <em>Abiraterone</em>-d4
  • HY-103687
    Abiraterone metabolite 1

    3β-OH-5α-Abi

    		 Drug Metabolite Cancer
    Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.
    <em>Abiraterone</em> metabolite 1
  • HY-157810
    AKR1C3-IN-11

    		Aldose Reductase Cancer
    AKR1C3-IN-11 (Compound 6e) is a Aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 2.0 μM. AKR1C3-IN-11 inhibit cell proliferation in combination with abiraterone (HY-70013). AKR1C3-IN-11 can be used for the research of prostate cancer .
    AKR1C3-IN-11
  • HY-137193
    5,6-Dihydroabiraterone

    		Drug Metabolite Cancer
    5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .
    5,6-Dihydroabiraterone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: